主要文件

查看所有文档

PZ0199

PD 0332991 羟乙基磺酸盐

Name: PD 0332991 羟乙基磺酸盐
Brand: SIGMA

≥98% (HPLC), powder, cyclin dependent kinases (CDK4, CDK6) inhibitor

别名:

6-乙酰基-8-环戊基-5-甲基-2 - [[5-（1-哌嗪基）-2-吡啶基]氨基]吡啶并[2,3-d]嘧啶-7（8H） - 酮2-羟基 - 乙磺酸（1：1）, 帕博西尼羟乙基磺酸盐

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₄H₂₉N₇O₂ · C₂H₆O₄S

化学文摘社编号:

827022-33-3

分子量:

573.66

UNSPSC Code:

12352200

PubChem Substance ID:

329823771

NACRES:

NA.77

MDL number:

MFCD22666589

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

PD 0332991 羟乙基磺酸盐, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

H₂O: 5 mg/mL, clear

storage temp.

room temp

SMILES string

OCCS(O)(=O)=O.CC(=O)C1=C(C)c2cnc(Nc3ccc(cn3)N4CCNCC4)nc2N(C5CCCC5)C1=O

InChI

1S/C24H29N7O2.C2H6O4S/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32;3-1-2-7(4,5)6/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29);3H,1-2H2,(H,4,5,6)

InChI key

LYYVFHRFIJKPOV-UHFFFAOYSA-N

Gene Information

human ... CCND1(595), CDK4(1019), CDK6(1021)

说明

Application

PD 0332991 羟乙基磺酸盐已被用于：

孵育 MCF10A 细胞以验证细胞周期蛋白 D1 抑制自噬与细胞周期蛋白依赖性激酶活性有关
作为细胞周期蛋白依赖性激酶 4 (CDK4) 抑制剂研究其在 果蝇中的抗惊厥属性
模拟 5α-双氢睾酮 (DHT) 对 HPr-1AR 细胞周期进程和生长的抑制作用。

Biochem/physiol Actions

PD 0332991 可能作为化学致敏剂。它与抗雌激素类药物一起用于治疗乳腺癌。已知 PD 0332991 也具有抗肿瘤作用。

PD 0332991 是 CDK4 和 CDK6 的强效选择性抑制剂。

PD 0332991 是细胞周期蛋白依赖性激酶 CDK4 和 CDK6 的强效选择性抑制剂，在体外 IC ₅₀ = 11 nM (CDK4) 和 16 nM (CDK6)。PD 0332991可诱导视网膜母细胞瘤 (Rb) 阳性肿瘤细胞的G1 期阻滞。

Features and Benefits

《受体分类和信号转导》手册的 CDK 页面有该化合物的介绍。想要浏览手册的其他页面，请单击此处。

Other Notes

化学探针门户网站已对 PD0332991 进行了专家评审和推荐。欲了解更多信息，请访问化学探针门户网站上的 PD0332991 探针摘要。

flash_point_f

Not applicable

flash_point_c

Not applicable

target_organs

Bone marrow,male reproductive organs

pictograms

GHS08,GHS09

signalword

Warning

hcodes

H341,H361f,H373,H411

pcodes

P202 - P260 - P273 - P280 - P308 + P313 - P391

Hazard Classifications

Aquatic Chronic 2 - Muta. 2 - Repr. 2 - STOT RE 2 Oral

存储类别

11 - Combustible Solids

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

047M4716V

072M4735V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

商品

Cyclin-dependent Kinases (CDKs)

Review properties, activators and inhibitors, and available products for researching cyclin-dependent kinases (CDKs).

Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.

Craig P Giacomini et al.

PLoS genetics, 9(4), e1003464-e1003464 (2013-05-03)

Gene fusions, like BCR/ABL1 in chronic myelogenous leukemia, have long been recognized in hematologic and mesenchymal malignancies. The recent finding of gene fusions in prostate and lung cancers has motivated the search for pathogenic gene fusions in other malignancies. Here

Ploidy-dependent change in cyclin D2 expression and sensitization to cdk4/6 inhibition in human somatic haploid cells.

Kan Yaguchi et al.

Biochemical and biophysical research communications, 504(1), 231-237 (2018-09-09)

Near-haploidy is observed in certain cancer types, but ploidy-dependent alterations in gene regulation in the haploid state remain elusive. Here, by comparative transcriptome analysis between human isogenic haploid and diploid cell lines, we found lowering of cyclin D2 level in

Palbociclib-induced autophagy and senescence in gastric cancer cells.

Claudio A Valenzuela et al.

Experimental cell research, 360(2), 390-396 (2017-09-28)

Targeting cyclin D-CDK4/6 kinase complexes has recently been shown to increase the survival of breast cancer patients with estrogen receptor positive breast tumors. Based on these outcomes, CDK4/6 inhibitors are currently being tested, alone o in combination with other drugs

查看所有相关文献

全球贸易项目编号

货号	GTIN
PZ0199-25MG	04061832449289
PZ0199-5MG	04061832449296